Navigation Links
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Date:7/22/2013

BOULDER, Colo., July 22, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report top-line results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013.  Ron Squarer, Chief Executive Officer, will lead the call.

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Conference Call InformationDate: Tuesday, July 23, 2013Time: 

9:00 a.m. eastern timeToll-Free: 

(888) 771-4371Toll: 

(847) 585-4405Pass Code: 

35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 CSSi, the ... for the clinical research industry, is proud to announce ... . The new website features both enriched content and ... experience and enhances the company,s already well-established position as ... "After many months of hard work, ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a ... held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As ... independent hearing healthcare providers to help them stay ahead in the industry. At the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to announce the launch ... Today, which will educate readers on how to take care of all aspects of ... is placed on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... executives in the life sciences, offering exclusive access to key decision makers who ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the ... versatile, patient-centric spinal cord stimulation system. The Nuvectraâ„¢ Algovita SCS System has been FDA ... to be the first in Arkansas to introduce the most powerful SCS system and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):